MADD

Across TCGA pan-cancer cohorts, MADD mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MADD data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MADD mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MADD expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where MADD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.564	0.918	.003	22	view →
UCEC	DFS	Tertile	All	1.000	0.845	.004	12	view →
PDAC	OS	Tertile	III,IV	0.722	0.308	.014	12	view →
CCRCC	OS	Median	III,IV	1.000	0.842	.041	6	view →
HNSC	DFS	Tertile	III,IV	0.490	0.749	.034	5	view →
GBM	DFS	Quartile	All	0.856	0.691	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MADD–LUAD (OS)

Open the LUAD breakdown →